NASDAQ:GERN Geron Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. $1.37 +0.01 (+0.74%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$1.33▼$1.4050-Day Range$1.19▼$1.5852-Week Range$0.99▼$1.74Volume8.94 million shsAverage Volume2.40 million shsMarket Capitalization$517.10 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address GERN Stock Forecast (MarketRank)Overall MarketRank™1.80 out of 5 starsMedical Sector801st out of 1,418 stocksPharmaceutical Preparations Industry397th out of 679 stocksAnalyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Geron has a forecasted upside of 301.5% from its current price of $1.37.Amount of Analyst CoverageGeron has received no research coverage in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesGeron has received 459 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGeron has received 201 “underperform” votes. (Add your “underperform” vote.)Community SentimentGeron has received 69.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote “Outperform” if you believe GERN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Geron is held by insiders.Percentage Held by Institutions47.75% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to decrease in the coming year, from ($0.37) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Geron (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock News HeadlinesJune 24, 2022 | nasdaq.comRadius (RDUS) to Go Private With $890M Deal, Shares Gain - NasdaqJune 24, 2022 | nasdaq.comNovartis' (NVS) Oncology Drugs Get Approval for Label Expansion - NasdaqJune 23, 2022 | usnews.comEU Leaders Accept Ukraine and Moldova as Membership Candidates - Official - U.S. News & World ReportJune 23, 2022 | nasdaq.comRadius (RDUS), Menarini Submit NDA for Breast Cancer Drug - NasdaqJune 17, 2022 | nasdaq.comBausch (BHC) Suspends IPO Plans for Solta Medical - NasdaqJune 17, 2022 | americanbankingnews.comGeron (NASDAQ:GERN) Share Price Crosses Above 200-Day Moving Average of $1.27June 16, 2022 | nypost.comAmerican tourist in stolen-watch incident faces probe in company's $5M bankruptcy case - New York Post June 15, 2022 | finance.yahoo.comGeron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role - Yahoo FinanceJune 15, 2022 | finance.yahoo.comGeron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor RoleJune 15, 2022 | businesswire.comGeron Corporation Announces Appointment of Faye Feller, M.D. to Chief Medical Officer and Transition of Aleksandra Rizo, M.D., Ph.D. to Senior Advisor Role - Business WireJune 15, 2022 | americanbankingnews.comHead-To-Head Review: Geron (NASDAQ:GERN) vs. Annexon (NASDAQ:ANNX)June 14, 2022 | chiefswire.usatoday.com4 Chiefs players to watch as mandatory minicamp begins - Chiefs WireJune 13, 2022 | chiefswire.usatoday.com4 takeaways following conclusion of Kansas City Chiefs OTAs - Chiefs WireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees69Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/24/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+301.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116.11 million Net Margins-8,584.92% Pretax Margin-8,584.92% Return on Equity-85.84% Return on Assets-52.28% Debt Debt-to-Equity Ratio0.51 Current Ratio3.77 Quick Ratio3.77 Sales & Book Value Annual Sales$1.39 million Price / Sales372.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book3.51Miscellaneous Outstanding Shares377,447,000Free Float354,800,000Market Cap$517.10 million OptionableOptionable Beta0.99 Geron Frequently Asked Questions Should I buy or sell Geron stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock. View analyst ratings for Geron or view top-rated stocks. What is Geron's stock price forecast for 2022? 4 analysts have issued twelve-month price targets for Geron's stock. Their GERN stock forecasts range from $4.00 to $7.00. On average, they expect Geron's stock price to reach $5.50 in the next year. This suggests a possible upside of 301.5% from the stock's current price. View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts. How has Geron's stock performed in 2022? Geron's stock was trading at $1.22 at the beginning of the year. Since then, GERN stock has increased by 12.3% and is now trading at $1.37. View the best growth stocks for 2022 here. When is Geron's next earnings date? Geron is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Geron. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company earned $0.12 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative trailing twelve-month return on equity of 85.84% and a negative net margin of 8,584.92%. During the same period last year, the company posted ($0.09) earnings per share. View Geron's earnings history. Who are Geron's key executives? Geron's management team includes the following people: Dr. John A. Scarlett M.D., Chairman, Pres & CEO (Age 71, Pay $1.26M)Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 53, Pay $743.27k)Dr. Andrew J. Grethlein, Exec. VP & COO (Age 58, Pay $767.28k)Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Operations & Chief Alliance Officer (Age 58, Pay $753.22k)Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 47, Pay $866.73k)Mr. Anil Kapur, Exec. VP of Corp. Strategy & Chief Commercial Officer (Age 52, Pay $654.89k)Ms. Suzanne Messere, Head of Investor Relations & Corp. CommunicationsMr. Stephen N. Rosenfield J.D., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 72)Ms. Shannon Odam, VP of HRMr. Edward E. Koval, Exec. VP & Chief Bus. Officer (Age 60) What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees. Who are some of Geron's key competitors? Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of GERN's competitors. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). What is Geron's stock symbol? Geron trades on the NASDAQ under the ticker symbol "GERN." Who are Geron's major shareholders? Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.59%), Vanguard Group Inc. (4.59%), State Street Corp (3.58%), Northern Trust Corp (0.79%), Bank of New York Mellon Corp (0.36%) and Bank of America Corp DE (0.26%). View institutional ownership trends for Geron. Which institutional investors are selling Geron stock? GERN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Bank of America Corp DE, Simplex Trading LLC, Northern Trust Corp, BNP Paribas Arbitrage SA, Group One Trading L.P., and GSA Capital Partners LLP. View insider buying and selling activity for Geron or view top insider-selling stocks. Which institutional investors are buying Geron stock? GERN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Renaissance Technologies LLC, Ergoteles LLC, Virtu Financial LLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., and Mercer Global Advisors Inc. ADV. View insider buying and selling activity for Geron or or view top insider-buying stocks. How do I buy shares of Geron? Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Geron's stock price today? One share of GERN stock can currently be purchased for approximately $1.37. How much money does Geron make? Geron (NASDAQ:GERN) has a market capitalization of $517.10 million and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116.11 million in net income (profit) each year or ($0.36) on an earnings per share basis. How many employees does Geron have? Geron employs 69 workers across the globe. How can I contact Geron? Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for Geron is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750. This page (NASDAQ:GERN) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here